These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 17896079)
1. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Omuro AM; Taillandier L; Chinot O; Carnin C; Barrie M; Hoang-Xuan K J Neurooncol; 2007 Nov; 85(2):207-11. PubMed ID: 17896079 [TBL] [Abstract][Full Text] [Related]
2. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235 [TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL). Salamoon M; Hussein T; Kenj M; Bachour M Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma. Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145 [TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Wong ET; Tishler R; Barron L; Wu JK Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999 [TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380 [TBL] [Abstract][Full Text] [Related]
7. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587 [TBL] [Abstract][Full Text] [Related]
8. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E Oncology; 2001; 60(2):134-40. PubMed ID: 11244328 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience. Wang XX; Huang HQ; Bai B; Cai QQ; Cai QC; Gao Y; Xia YF; Xia ZJ; Jiang WQ Leuk Lymphoma; 2014 Nov; 55(11):2497-501. PubMed ID: 24605911 [TBL] [Abstract][Full Text] [Related]
10. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122 [TBL] [Abstract][Full Text] [Related]
11. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
12. Pemetrexed for primary central nervous system lymphoma in the elderly. Han S; Wang M; Liu B; Yu J Clin Transl Oncol; 2016 Feb; 18(2):138-43. PubMed ID: 26169215 [TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634 [TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate for primary CNS lymphoma in the elderly. Ng S; Rosenthal MA; Ashley D; Cher L Neuro Oncol; 2000 Jan; 2(1):40-4. PubMed ID: 11302253 [TBL] [Abstract][Full Text] [Related]
15. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567 [TBL] [Abstract][Full Text] [Related]
16. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253 [TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744 [TBL] [Abstract][Full Text] [Related]
18. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571 [TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Omuro AM; DeAngelis LM; Yahalom J; Abrey LE Neurology; 2005 Jan; 64(1):69-74. PubMed ID: 15642906 [TBL] [Abstract][Full Text] [Related]